{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "randomized controlled trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "A multicenter, double-blind, randomized controlled trial was conducted."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were hospitalized patients at risk of AKI, with eligibility criteria including age over 18 and no pre-existing chronic kidney disease."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received biomarker-guided management, while the control group received standard care."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the efficacy of novel biomarkers in the early diagnosis and prognosis of acute kidney injury (AKI)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of AKI within 48 hours, assessed by serum creatinine levels."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was performed using a computer-generated sequence, with allocation concealment ensured by sealed envelopes."
      },
      "Blinding": {
        "score": 2,
        "evidence": "double-blind"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomized, with 100 in each group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 98 participants in the intervention group and 97 in the control group using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group showed a significant reduction in AKI incidence (mean difference = 5.2%, 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 3% of the intervention group and 1% of the control group, with mild gastrointestinal side effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678."
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the National Institutes of Health."
      }
    },
    "total_score": 24,
    "max_score": 25
  },
  "model": "gpt-4o"
}